<code id='610E416FD9'></code><style id='610E416FD9'></style>
    • <acronym id='610E416FD9'></acronym>
      <center id='610E416FD9'><center id='610E416FD9'><tfoot id='610E416FD9'></tfoot></center><abbr id='610E416FD9'><dir id='610E416FD9'><tfoot id='610E416FD9'></tfoot><noframes id='610E416FD9'>

    • <optgroup id='610E416FD9'><strike id='610E416FD9'><sup id='610E416FD9'></sup></strike><code id='610E416FD9'></code></optgroup>
        1. <b id='610E416FD9'><label id='610E416FD9'><select id='610E416FD9'><dt id='610E416FD9'><span id='610E416FD9'></span></dt></select></label></b><u id='610E416FD9'></u>
          <i id='610E416FD9'><strike id='610E416FD9'><tt id='610E416FD9'><pre id='610E416FD9'></pre></tt></strike></i>

          entertainment

          entertainment

          author:hotspot    Page View:2996
          Tome cofounders Jonathan Gootenberg, left, and Omar Abudayyeh, a scientific team that's trying to reinvent gene editing for a new era of biotech innovation.
          Suzanne Kreiter/Globe staff

          WATERTOWN — Their brainstorming began in an MIT class in 2010 when the eager undergrads shot each other emails about how to solve a bioengineering equation. It has continued for 14 years over sushi dinners, between Marvel movies, and during rowing-machine workouts.

          Together, Omar Abudayyeh, 33, and Jonathan Gootenberg, 32, have probed the mysteries of genomic editing and COVID detection. They co-published 10 scientific papers, helped launch two medical-diagnostic companies, and cofounded a Watertown startup, Tome Biosciences, that reengineers genes and cells to cure diseases. They also run the Abudayyeh-Gootenberg Lab at Harvard.

          advertisement

          Gootenberg and Abudayyeh are an unusual pair, two scientists — a Jewish American and a Palestinian American — who prefer working together in a field that often draws solitary researchers and rewards individual achievement.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more
          FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy
          FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

          PeterMarks,theFDA'stopregulatorofgenetherapies(right),speakswithSTAT'sAdamFeuersteininSanFrancisco.S

          read more
          Hollywood unions extend contract negotiations for actors
          Hollywood unions extend contract negotiations for actors

          1:36HollywoodwritersandtheirsupportersfromtheSAGAFTRAactors'unionwalkthepicketlineoutsideWarnerBrosS

          read more

          ADA: All diabetes patients should be screened for liver condition

          HyacinthEmpinado/STATSANDIEGO — TheAmericanDiabetesAssociationsaidSundaythatalladultswithtype2diabet